The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).

Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

PersonnelTakeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 202630-Jan-2025 / 09:31 CET/CESTDisclosure of an inside information acc. to Article 17 ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ...

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda ...

BusinessWire India Mumbai Vashi Maharashtra [India] January 31 Zydus Takeda Healthcare Private Limited ZTHPL a joint venture company set up by Zydus Lifesciences Limited and Takeda Pharmaceutical Comp ...

Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences Limited and Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502/NYSE:TAK), celebrates the ...

Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...

Takeda Pharmaceutical named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but growing ranks of women leading Japanese companies.

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...